NEW YORK — German molecular diagnostics firm Epigenomics on Thursday reported a 28 percent drop in first quarter revenues as orders for its test kits by US customers fell amid reimbursement uncertainty.
For the three-month period ended March 31, Epigenomics' revenues dropped to €239,000 ($257,358) from €331,000 in the same quarter last year. Sales of products, including the firm's US Food and Drug Administration-approved blood test for colorectal cancer screening Epi proColon, were down 32 percent to €219,000 from €322,000.